Work

Abstract PS1-12-13: Real-world rate of switching and reasons for switching among CDK4/6i drugs among first-line metastatic HR+/HER2- breast cancer patients

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps1-12-13

Authors: S. Reganti, R. Choksi, V. Gorantla, F. Kudrik, D. Patt, S. Reddy, S. Rosenfeld, D. Parris, M. Wang, A. Rui, M. Gart, C. Wall, B. Wang, P. Varughese, J. Donegan, L. Morere, R. Geller, J. Scott, R. Mahtani

Institutions: University of Pittsburgh Medical Center, South Carolina Oncology Associates, Texas Oncology, Highlands Oncology Group, Integra (United States), Baptist Hospital of Miami, Baptist Health South Florida

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129621512

Cites:

Cited by:

Related to: